Substance P and substance P receptor antagonists in the pathophysiology and therapy of affective disorders;Substanz P und substanz-P-rezeptorantagonisten in der pathogenese und therapie affektiver störungen

Nervenheilkunde

Volumn 21, Issue 10, 2002, Pages 493-496

  Lieb, Klaus ^a   Herpfer, I ^a   Fiebich, B L ^a   Berger, M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Depression; Serotonin; Substance P; Substance P receptor antagonists

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; PLACEBO; SUBSTANCE P; SUBSTANCE P ANTAGONIST;

AFFECTIVE NEUROSIS; ANXIETY NEUROSIS; BLOOD LEVEL; CEREBROSPINAL FLUID; CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; HIPPOCAMPUS; HUMAN; NERVOUS SYSTEM DEVELOPMENT; NORADRENERGIC SYSTEM; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SEROTONINERGIC SYSTEM;

EID: 0036928145     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Berrettini WH, Rubinow DR, Nurnberger JI, Simmons-Alling S, Post RM, Gershon ES. CSF substance P immunoreactivity in affective disorders. Biol Psychiatry 1985; 20: 965-70.
2. Burnet PW, Harrison PJ. Substance P (NK1) receptors in the cingulate cortex in unipolar and bipolar mood disorder and schizophrenia. Biol Psychiatry 2000; 47: 80-3.
3. Coiro V, Capretti L, Volpi R, Davoli C, Marcato A, Cavazzini U, Caffarri G, Rossi G, Chiodera P. Stimulation of ACTH/cortisol by intravenously infused substance P in normal men: Inhibition by sodium valproate. Neuroendocrinology 1992; 56: 459-63.
4. De Felipe C, Herrero JF, O'Brien JA, Palmer JA, Doyle CA, Smith AJ, Laird JM, Belmonte C, Cervero F, Hunt SP. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 1998; 392: 394-7.
5. Feuerstein TJ, Gleichauf O, Landwehrmeyer GB. Modulation of cortical acetylcholine release by serotonin: The role of substance P interneurons. Naunyn Schmiedebergs Arch Pharmacol 1996; 354: 618-26.
6. Froger N, Gardier AM, Moratalla R, Alberti I, Lena I, Boni C, De Felipe C, Rupniak NM, Hunt SP, Jacquot C, Hamon M, Lanfumey L. 5-Hydroxytryptamine (5-HT) 1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J Neurosci 2001; 21: 8188-97.
7. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Rupniak NM. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-5.
8. Lieb K, Ahlvers K, Dancker K, Strohbusch S, Reincke M, Feige B, Berger M, Riemann D, Voderholzer U. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young man. Neuropsychopharmacology 2002 (in press).
9. Maubach KA, Martin K, Chicchi G, Harrison T, Wheeldon A, Swain CJ, Cumberbatch MJ, Rupniak NM, Seabrook GR. Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus. Neuroscience 2002; 109: 609-17.
10. Millan MJ, Lejeune F, De Nanteuil G, Gobert A. Selective blockade of neurokinin (NK) (1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats. J Neurochem 2001; 76: 1949-54.
11. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ. Reduction of cisplatin-induced emesis by a selective neurokinin-1- receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med 1999; 340: 190-5.
12. Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiological Reviews 1993; 73: 229-308.
13. Pioro EP. Distribution of substance P and enkephalin immunoreactive neurons and fibers. In: Paxinos G (ed.). The Human Nervous System. San Diego: Academic press 1990: 1051-94.
14. Quartara L, Maggi CA. The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles. Neuropeptides 1998; 32: 1-49.
15. Rimon R, Le Greves P, Nyberg F, Heikkila L, Salmela L, Terenius L. Elevation of substance P-like peptides in the CSF of psychiatric patients. Biol Psychiatry 1984; 19: 509-16.
16. Rupniak NM. Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. Curr Opin Investig Drugs 2002; 3: 257-61.
17. Rupniak NM, Kramer MS. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 1999; 20: 485-90.
18. Russell IJ. Neurochemical pathogenesis of fibromyalgia. Z Rheumatol 1998; 7, suppl. 2: 63-6.
19. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis & Rheumatism 1994; 37: 1593-601.
20. Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R, Heath MJ. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci USA 2001; 98: 1912-7.
21. Schedlowski M, Fluge T, Richter S, Tewes U, Schmidt RE, Wagner TO. Beta-endorphin, but not substance-P, is increased by acute stress in humans. Psychoneuroendocrinology 1995; 20: 103-10.
22. Stockmeier CA, Konick LC, Shi X, Overholser JC, Meltzer HY, Jurjus GJ, Friedman L, Rajkowska G. Neurokinin-1 receptors are decreased in orbitofrontal cortex (ORB) in major depression. Soc Neurosci Abs 2002; 27: 309.
23. Vaupel R, Jarry H, Schlomer HT, Wuttke W. Differential response of substance P-containing subtypes of adrenomedullary cells to different stressors. Endocrinology 1988; 123: 2140-5.
24. Weiss DW, Hirt R, Tarcic N, Berzon Y, Ben Zur H, Breznitz S, Glaser B, Grover NB, Baras M, O'Dorisio TM. Studies in psychoneuroimmunology: Psychological, immunological, and neuroendocrinological parameters in Israeli civilians during and after a period of Scud missile attacks. Behav Med 1996; 22: 5-14.